Advertisement

Topics

Double Blessing Or Double Whammy - What Awaits AMAG?

11:10 EST 31 Jan 2018 | RTTNews

Shares of AMAG Pharmaceuticals Inc. (AMAG) are nearly 43% down from its 52-week high of $25.20 that was recorded on March 8, 2017. With two of the Company's drugs awaiting FDA decision for label expansion, there could be some sharp movement in the level of its stock price in February, depending upon the outcomes.

Original Article: Double Blessing Or Double Whammy - What Awaits AMAG?

NEXT ARTICLE

More From BioPortfolio on "Double Blessing Or Double Whammy - What Awaits AMAG?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...